RheumatologyPub Date : 2025-05-01DOI: 10.1093/rheumatology/keae466
Koichi Yamaguchi, Paul Poland, Lei Zhu, Siamak Moghadam-Kia, Rohit Aggarwal, Toshitaka Maeno, Akihiko Uchiyama, Sei-Ichiro Motegi, Chester V Oddis, Dana P Ascherman
{"title":"Comparative B cell epitope profiling in Japanese and North American cohorts of MDA5+ dermatomyositis patients reveals a direct association between immune repertoire and pulmonary mortality.","authors":"Koichi Yamaguchi, Paul Poland, Lei Zhu, Siamak Moghadam-Kia, Rohit Aggarwal, Toshitaka Maeno, Akihiko Uchiyama, Sei-Ichiro Motegi, Chester V Oddis, Dana P Ascherman","doi":"10.1093/rheumatology/keae466","DOIUrl":"10.1093/rheumatology/keae466","url":null,"abstract":"<p><strong>Objectives: </strong>Anti-melanoma differentiation-associated gene 5 antibody-positive (MDA5+) DM patients exhibit clinical features that vary by geographical and ethnic/genetic distribution. The objective of this study was to investigate whether B cell epitope profiles and corresponding clinical features distinguished two independent cohorts of MDA5+ DM.</p><p><strong>Methods: </strong>ELISA-based methods were used to determine the relationship between antibody recognition of 155 overlapping amino acid MDA5 subfragments and clinical features of 17 MDA5+ DM patients from Japan. Associations between clinical features and standardized anti-MDA5 subfragment antibody titres were assessed via Brunner Munzel testing and compared with the clinical/serological profiles of an independent North American cohort. Receiver operater characteristic (ROC) analyses and Kaplan-Meier curves were used to further assess the relationship between anti-MDA5 fragment antibody levels and specific clinical features/outcomes.</p><p><strong>Results: </strong>Clinical characterization of a Japanese cohort of 17 MDA5+ DM patients revealed a high prevalence of arthritis (47%) and interstitial lung disease (ILD) (100%). Serological profiling demonstrated predominant antibody recognition of MDA5 fragments A (aa 1-155), B (aa 130-284) and E (aa 517-671) in a pattern that was distinct from North American MDA5+ patients (n = 24), whose sera preferentially recognized fragment H (aa 905-1026). Statistical analysis revealed a striking association between anti-fragment A antibody levels and rapidly progressive ILD (RP-ILD) among Japanese patients (P < 0.01). ROC and Kaplan-Meier curves also demonstrated a strong relationship between anti-fragment A antibody levels, RP-ILD, and pulmonary death in combined cohort analyses.</p><p><strong>Conclusions: </strong>Japanese and North American MDA5+ DM patients manifest markedly different B cell epitope profiles that are associated with higher prevalence of RP-ILD and worse clinical outcome among Japanese patients.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"2953-2960"},"PeriodicalIF":4.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RheumatologyPub Date : 2025-05-01DOI: 10.1093/rheumatology/keae559
Dalena Chu, Noa Schwartz, Jeanette Ampudia, Joel Guthridge, Judith James, Jill P Buyon, Stephen Connelly, Maple Fung, Cherie T Ng, Andrea Fava, Michelle Petri, Chandra Mohan, Chaim Putterman
{"title":"Soluble urine activated leukocyte cell adhesion molecule is a strong predictor of lupus nephritis.","authors":"Dalena Chu, Noa Schwartz, Jeanette Ampudia, Joel Guthridge, Judith James, Jill P Buyon, Stephen Connelly, Maple Fung, Cherie T Ng, Andrea Fava, Michelle Petri, Chandra Mohan, Chaim Putterman","doi":"10.1093/rheumatology/keae559","DOIUrl":"10.1093/rheumatology/keae559","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate urinary activated leucocyte cell adhesion molecule (ALCAM) and CD6 as predictors of LN progression or disease resolution across a 1-year study.</p><p><strong>Methods: </strong>Serum and urine samples from biopsy proven LN subjects (n = 122) were prospectively collected over the course of a year at 3- or 6-month intervals (weeks 0, 12, 26 and 52) across multiple study sites and assessed for soluble ALCAM and CD6 levels. Urine creatinine from the same urine sample was used to normalize the levels of urinary ALCAM and urinary CD6. Measured levels of serum and urine ALCAM and CD6 were then analysed against disease metrics cross-sectionally and longitudinally.</p><p><strong>Results: </strong>Cross-sectional analysis at baseline revealed that urinary ALCAM significantly correlated with urine protein creatinine ratio, renal SLEDAI, and the Physician Global Assessment (PGA), and negatively correlated with serum C3 and C4. Receiver operating characteristic curve analysis demonstrated that urinary ALCAM is a predictor of LN with an area under the curve (AUC) of 0.97, compared with urinary CD6 with an AUC of 0.71. Importantly, the change in urinary ALCAM over a 3-month period distinguished between non-responders and responders at week 52.</p><p><strong>Conclusion: </strong>Urinary ALCAM is reflective of changes in LN and may be predictive of response status.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"2676-2687"},"PeriodicalIF":4.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12048083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142473622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RheumatologyPub Date : 2025-05-01DOI: 10.1093/rheumatology/keae685
Mehmet Nur Kaya, Duygu Tecer
{"title":"Comment on: Association between depression and anxiety and inability to achieve remission in rheumatoid arthritis and psoriatic arthritis.","authors":"Mehmet Nur Kaya, Duygu Tecer","doi":"10.1093/rheumatology/keae685","DOIUrl":"10.1093/rheumatology/keae685","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"3217-3218"},"PeriodicalIF":4.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RheumatologyPub Date : 2025-05-01DOI: 10.1093/rheumatology/keaf110
Jacob Corum Williams, Uazman Alam, Sizheng Steven Zhao
{"title":"Incidence of uveitis and inflammatory bowel disease in psoriatic disease, and psoriatic disease in uveitis and inflammatory bowel disease.","authors":"Jacob Corum Williams, Uazman Alam, Sizheng Steven Zhao","doi":"10.1093/rheumatology/keaf110","DOIUrl":"10.1093/rheumatology/keaf110","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"3177-3179"},"PeriodicalIF":4.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12048042/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RheumatologyPub Date : 2025-05-01DOI: 10.1093/rheumatology/keae659
Christopher P Denton
{"title":"Comment on: The 2024 British Society for Rheumatology guideline for management of systemic sclerosis. Reply.","authors":"Christopher P Denton","doi":"10.1093/rheumatology/keae659","DOIUrl":"10.1093/rheumatology/keae659","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"3196-3197"},"PeriodicalIF":4.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RheumatologyPub Date : 2025-05-01DOI: 10.1093/rheumatology/keaf127
{"title":"Correction to: Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis.","authors":"","doi":"10.1093/rheumatology/keaf127","DOIUrl":"10.1093/rheumatology/keaf127","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"3172"},"PeriodicalIF":4.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143650104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"68Ga-FAPI and 18F-NaF PET/CT in psoriatic arthritis: a comparative study.","authors":"Fan Yang, Chaofan Lu, Qingqing Pan, Rui Zhang, Meng Yang, Qian Wang, Mengtao Li, Xiaofeng Zeng, Yaping Luo, Xiaomei Leng","doi":"10.1093/rheumatology/keae577","DOIUrl":"10.1093/rheumatology/keae577","url":null,"abstract":"<p><strong>Objectives: </strong>As fibroblast-like synoviocyte activation and bone formation are associated with PsA, PET using the tracers of 68Ga-fibroblast activation protein inhibitor (FAPI) and 18F-sodium fluoride (NaF) may sensitively detect the disease. In this prospective study, we aimed to evaluate the performance of 68Ga-FAPI PET/CT in PsA and to compare it with 18F-NaF PET/CT.</p><p><strong>Methods: </strong>Sixteen participants (female 7/16, age 42.31 ± 10.66 years) with PsA were prospectively enrolled and underwent dual-tracer PET/CT, clinical assessment and ultrasonography. PET/CT images were scored for PET-positive lesions at the peripheral joints, entheses, and axial joints.</p><p><strong>Results: </strong>The positivity rate of 68Ga-FAPI in peripheral joints was higher than that in entheses and axial joints (21.84% vs 12.15% vs 0%), whereas high positivity rates of 18F-NaF in peripheral joints, entheses, and axial joints were observed (85.23%, 78.13% and 75%, respectively). The DAS 28 was higher in the PET-positive than in the PET-negative group with 68Ga-FAPI (5.25 ± 1.84 vs 2.55 ± 0.94, P = 0.037), but not with 18F-NaF. In addition, the PET joint count at 68Ga-FAPI PET/CT was positively correlated with the tender joint count (r = 0.604, P = 0.017), swollen joint count (r = 0.773, P = 0.001), DAS28-CRP (r = 0.556, P = 0.032), Psoriatic Arthritis Disease Activity Score (PASDAS) (r = 0.540, P = 0.038) and PsASon13 (r = 0.701, P = 0.005), while no correlation was observed in 18F-NaF PET/CT.</p><p><strong>Conclusion: </strong>The positivity rates of 68Ga-FAPI- and 18F-NaF PET/CT were different in patients with PsA in peripheral joints, entheses, and axial joints. The extent of joint involvement as shown in 68Ga-FAPI PET/CT correlated with clinical and US variables as well as with disease activity.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, http://clinicaltrials.gov, NCT05686876.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"2575-2582"},"PeriodicalIF":4.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12048064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RheumatologyPub Date : 2025-05-01DOI: 10.1093/rheumatology/keae644
Javier Narváez, Marta Domínguez, Eva Galíndez, Javier Mendizábal, Lydia Abasolo, Judith Lluch, Javier Loricera, Noemí Garrido, Santos Castañeda, Patricia Moya, Carmen Larena, Paula Estrada, Carlos Galisteo, Anne Riveros Frutos, Francisco Ortiz Sanjuán, Tarek Salman, Margarida Vasques Rocha, Carlota L Iñiguez, María García González, Ricardo Blanco
{"title":"Sustained drug-free remission in giant cell arteritis.","authors":"Javier Narváez, Marta Domínguez, Eva Galíndez, Javier Mendizábal, Lydia Abasolo, Judith Lluch, Javier Loricera, Noemí Garrido, Santos Castañeda, Patricia Moya, Carmen Larena, Paula Estrada, Carlos Galisteo, Anne Riveros Frutos, Francisco Ortiz Sanjuán, Tarek Salman, Margarida Vasques Rocha, Carlota L Iñiguez, María García González, Ricardo Blanco","doi":"10.1093/rheumatology/keae644","DOIUrl":"10.1093/rheumatology/keae644","url":null,"abstract":"<p><strong>Objectives: </strong>The objectives of this study were to evaluate the frequency and timing of sustained drug-free remission (SDFR) in patients with GCA and to identify potential predictive factors of this outcome.</p><p><strong>Methods: </strong>A retrospective review of all patients included in the large Spanish multicentre registry for GCA (ARTESER) with at least 2 years of follow-up was undertaken. SDFR was defined as the absence of typical signs, symptoms, or other features of active GCA for ≥12 months after discontinuation of treatment.</p><p><strong>Results: </strong>We included 872 patients. Forty-seven percent had received concomitant treatment with tocilizumab and/or immunosuppressants, mainly MTX. SDFR was achieved in 21.2% (185/872) of the patients. The cumulative rates of patients achieving SDFR at 2, 3 and 4 years were 6.3%, 20.5% and 25.3%, respectively. Patients who achieved SDFR could reduce their prednisone dosage to 10 mg/day (P = 0.090) and 5 mg/day (P = 0.002) more quickly than those who did not. Relapses were less frequent in patients with SDFR (P = 0.006). The presence of relapses [incident rate ratio (IRR): 0.492, P < 0.001] and the need for i.v. methylprednisolone boluses at diagnosis (IRR: 0.575, P = 0.003) were significantly associated with a decreased likelihood of achieving SDFR. Only 5 patients (2.7%) experienced a recurrence, with a median onset of 19 months after achieving SDFR (interquartile range 25th-75th: 14-35 months).</p><p><strong>Conclusion: </strong>Within 3-4 years of diagnosis, only one-quarter of patients with GCA successfully reached the SDFR. Once the SDFR was achieved, the likelihood of experiencing recurrence was low. Relapses and the need for glucocorticoid boluses appear to have been predictors of the need for long-term glucocorticoids.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"2919-2927"},"PeriodicalIF":4.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142732040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comment on: Association between colchicine use and adverse cardiovascular events in patients with gout: a nationwide nested case-control study.","authors":"Shih-Wei Lai, Bing-Fang Hwang, Chiu-Shong Liu, Kuan-Fu Liao","doi":"10.1093/rheumatology/keae625","DOIUrl":"10.1093/rheumatology/keae625","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"3213-3214"},"PeriodicalIF":4.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
RheumatologyPub Date : 2025-05-01DOI: 10.1093/rheumatology/keaf018
Qing-Ying Fang, Liu-Qin Liang, Qian Qiu, Fan Lian
{"title":"A rare case of undifferentiated connective tissue disease presenting with polyserositis.","authors":"Qing-Ying Fang, Liu-Qin Liang, Qian Qiu, Fan Lian","doi":"10.1093/rheumatology/keaf018","DOIUrl":"10.1093/rheumatology/keaf018","url":null,"abstract":"","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"3191-3193"},"PeriodicalIF":4.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142954115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}